https://orcid.org/0000-0003-1149-3835
References
- Esposito S, Gnocchi M, Gagliardi M, et al. Therapeutic strategies against COVID-19. Acta Biomed. 2020;91(3):e2020038.
- EMA. COVID-19 treatments. Available from https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-treatments.
- European Centre for Disease Prevention and Control. Guidance on the provision of support for medically and socially vulnerable populations in EU/EEA countries and the United Kingdom during the COVID-19 pandemic, 3 July 2020. Stockholm: ECDC; 2020.
- Annex 1, Summary of product characteristics (Paxlovid). Available from https://www.ema.europa.eu/en/documents/product-information/paxlovid-epar-product-information_en.pdf.
- Annex 1, Summary of product characteristics (Veklury). Available from https://www.ema.europa.eu/en/documents/product-information/paxlovid-epar-product-information_en.pdf.
- Annex 1, Summary of product characteristics (Regkirona). Available from https://www.ema.europa.eu/en/documents/product-information/regkirona-epar-product-information_en.pdf.
- Annex 1, Summary of product characteristics (Ronapreve). Available from https://www.ema.europa.eu/en/documents/product-information/ronapreve-epar-product-information_en.pdf.
- Annex 1, Summary of product characteristics (Xevudy). Available at https://www.ema.europa.eu/en/documents/product-information/xevudy-epar-product-information_en.pdf.
- Annex 1, Summary of product characteristics (Evusheld). Available from https://www.ema.europa.eu/en/documents/product-information/evusheld-epar-product-information_en.pdf.
- EMA. Assessment report (molnupiravir). Available from https://www.ema.europa.eu/en/documents/referral/lagevrio-also-known-molnupiravir-mk-4482-covid-19-article-53-procedure-assessment-report_en.pdf.
- Annex 1, Summary of product characteristics (Kineret). Available from https://www.ema.europa.eu/en/documents/product-information/kineret-epar-product-information_en.pdf.
- Annex 1, Summary of product characteristics (RoActemara). Available from https://www.ema.europa.eu/en/documents/product-information/roactemra-epar-product-information_en.pdf.
- Annex 1, Summary of product characteristics (Olumiant) https://www.ema.europa.eu/en/documents/product-information/olumiant-epar-product-information_en.pdf.
- COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available from https://www.covid19treatmentguidelines.nih.gov/.
- The National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing COVID-19. Available at https://www.nice.org.uk/guidance/ng191.
- AIFA. Reccomendations on medinicines to be used in home management of COVID-19 cases. Available from https://www.aifa.gov.it/documents/20142/1269602/EN_Raccomandazioni_AIFA_gestione_domiciliare_COVID-19_Vers7_12.04.2022.pdf.
- WHO. Therapeutics and COVID-19: living guidance, 16 September 2022. Available from https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.5.
- WHO. Living guidance for clinical management of COVID-19, 23 November 2021. Available from https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2.
- AIFA. Treatments to be used in COVID-19 patients in a hospital setting. Available from https://www.aifa.gov.it/documents/20142/1269602/SOC_ospedaliera_04.10.2021_EN.pdf.
- Venkatesan P. European guideline on managing adults in hospital with COVID-19. Lancet Respir Med. 2021;9(5):e50.
- Chalmers JD, Crichton ML, Goeminne PC, et al. Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. Eur Respir J. 2021;57(4):2100048.
- Shin HS. Empirical treatment and prevention of COVID-19. Infect Chemother. 2020;52(2):142–153.
- Takashita E, Yamayoshi S, Simon V, et al. Efficacy of antibodies and antiviral drugs against Omicron BA.2.12.1, BA.4, and BA.5 subvariants. N Engl J Med. 2022;387(5):468–470.
- Lai CC, Wang YH, Kuang-Hung Chen KH, et al. The clinical efficacy and safety of anti-viral agents for non-hospitalized patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials. Viruses. 2022;14(8):1706.
- Pitre T, Van Alstine R, Chick G, et al. The clinical efficacy and safety of anti-viral agents for non-hospitalized patients with COVID-19: antiviral drug treatment for nonsevere COVID-19: a systematic review and network Meta-analysis. CMAJ. 2022;194(28):E969–E980.
- Queensland Government, Department of Health. COVID-19 Treatment Guidelines for mild-moderate disease (Adults). July 2022.
- Wong CKH, Au ICH, Lau KTK, et al. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong’s omicron BA.2 wave: a retrospective cohort study. Lancet Infect Dis. 2022;2022: S1473-3099(22)00507-2.